GBA Presents: RADIO SAVANT-!

[TrailerParkTed]

another pump like ENVX?

-- Ahem. Insider buying is a pump?, a new factory ready to go is a pump? The best battery tech available today is a pump...? You noticed I fled the name!

WHAT A WEEK FOR GBA!!! Do you guys notice when I take a few days off I always kill it when I return? This happened last time...

something to think about.

No disrespect meant on ENVX, your Social Media groupies were promoting it everywhere.

 

[stonedinvestor]

TGLS Tecnoglass Inc. On watch from our new friend.
$40.21 1.37(+3.53%)

 

[stonedinvestor]

ETNB $16.83 (+23%)<----

Sorry I missed this. will add to review.


ETNB 89bio, Inc.
$15.81

 

[stonedinvestor]

*****GBA Buy->Enerpac Tool Group Corp. (EPAC)/ selling off after decent earn-- gobble gobble.
NYSE - Nasdaq Real Time Price. Currency in USD

$23.96-3.73(-13.47%)<----- GO TIME-!

This is moving very slow We'll get a lousy $2 out of it.> exit today.

 

[TrailerParkTed]

VKTX did a shelf offering yesterday, how come no big price tank? I figured the gods were shorting it at $16 all morning knowing they could buy back at $14.


SQ, I bought the $67 calls yesterday at $1.08 ave. SQ was $66.50-$67 when I bought. The $70 calls were like 10,000 contracts.

 

[stonedinvestor]

And for real Stoney... we are going lower.
You confuse near term volatility with the bigger picture.
Just watch. You'll see.

When we hit 4200, I'll end this thread.

March 22 Vz you went all negative on me! 3,800 was on the way. Whoops!

WHAT SAY YOU NOW!! I do need some of your imput -- and I do value it (when you are being serious)

ARE THINGS LOOKING UP! // WILL WE REACH 4,200? marketwatch wants to know.

 

[stonedinvestor]

VKTX did a shelf offering yesterday, how come no big price tank? I figured the gods were shorting it at $16 all morning knowing they could buy back at $14.


SQ, I bought the $67 calls yesterday at $1.08 ave. SQ was $66.50-$67 when I bought. The $70 calls were like 10,000 contracts.

View attachment 310506

I know you know the whole SQ story. There was a Hindenberg report Short report.

HF got in beginning of week when it sold off. It's a good name. (I think)

It fell from $74 area. It was almost $78 prior. Dropped to 58 -- just back of envelope that's $20/divide by 2 = $10 // $10 up from $58 is $68 <-- That's fair value.

 

[stonedinvestor]

This is another insider buy situation i gave you guys.


ERAS Erasca, Inc.
$2.96 +0.22(+8.03%)

NASDAQ |$USD |Pre-Market:$3.12+0.16(+5.41%)<-- On the move again!

 

[stonedinvestor]

STOCK OF THE DAY- ERasca.
$3.58

Erasca initiated with a Buy at Goldman Sachs 04:43 ERAS Goldman S

(old news)
we reported four responses in nine patients with BRAF-driven tumors to either monotherapy ERAS-007 or ERAS-601. Three of these responses were in tumors with BRAF Class 2 or 3 alterations, including a confirmed response to monotherapy SHP2 inhibition in a patient with a BRAF Class 3 alteration, which is dependent on upstream receptor tyrosine kinase activation. We look forward to exploring the potential to address the high unmet need in these BRAF subtypes, which have no approved targeted therapies and represent up to 25% of all BRAF-driven tumors."

Dec 20---> Erasca announces first patient dosed in HERKULES-1 Phase 1b trial 12/20 ERAS Erasca announced dosing of the first patient in the HERKULES-1 Phase 1b trial evaluating ERK1/2 inhibitor ERAS-007 in combination with SHP2 inhibitor ERAS-601 in patients with RAS/MAPK pathway-altered solid tumors.

Feb 3->Erasca upgraded to Overweight from Equal Weight at Morgan Stanley 02/03 ERAS Morgan Stanley analyst Jeffrey Hung upgraded Erasca to Overweight from Equal Weight with a $15 price target. The analyst says the company recently bolstered its pipeline with naporafenib and has multiple data readouts expected this year. The firm now has greater confidence in Erasca's pipeline both on potential time to market and probability of success with the addition of naporafenib.

IDEA #3 ERAS $3.60

I think it may be a real buy here*** as it is lower than when we highlighted it.

 

[stonedinvestor]

Company Profile

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.